** Shares of healthcare software developer TRHC.O fall
9.6% to $33.50 after market
** Co's Q3 rev falls 5% to $70.5 mln as COVID-19 related
delays hampered demand for medication safety services (https://refini.tv/2TOkEp1)
** Q3 net loss widens to $21.6 mln from $8.1 mln a year ago
due to depreciation and amortization cost of $12.2 mln - TRHC
** Expects full-year revenue in range of $294 mln to $296
mln
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))